- Home
- EHC vs LEGN Comparison
EHC vs LEGN Comparison
Compare EHC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHC
- LEGN
- Stock Information
- Founded
- EHC 1983
- LEGN 2014
- Country
- EHC United States
- LEGN United States
- Employees
- EHC N/A
- LEGN N/A
- Industry
- EHC Hospital/Nursing Management
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- EHC Health Care
- LEGN Health Care
- Exchange
- EHC Nasdaq
- LEGN Nasdaq
- Market Cap
- EHC 12.3B
- LEGN 5.4B
- IPO Year
- EHC 1986
- LEGN 2020
- Fundamental
- Price
- EHC $119.04
- LEGN $35.64
- Analyst Decision
- EHC Strong Buy
- LEGN Strong Buy
- Analyst Count
- EHC 8
- LEGN 13
- Target Price
- EHC $123.38
- LEGN $75.17
- AVG Volume (30 Days)
- EHC 662.2K
- LEGN 2.0M
- Earning Date
- EHC 08-04-2025
- LEGN 08-08-2025
- Dividend Yield
- EHC 0.57%
- LEGN N/A
- EPS Growth
- EHC 30.58
- LEGN N/A
- EPS
- EHC 4.84
- LEGN N/A
- Revenue
- EHC $5,512,600,000.00
- LEGN $728,303,000.00
- Revenue This Year
- EHC $10.73
- LEGN $65.49
- Revenue Next Year
- EHC $8.61
- LEGN $53.76
- P/E Ratio
- EHC $24.49
- LEGN N/A
- Revenue Growth
- EHC 11.21
- LEGN 112.46
- 52 Week Low
- EHC $82.74
- LEGN $27.34
- 52 Week High
- EHC $123.13
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- EHC 47.24
- LEGN 57.79
- Support Level
- EHC $117.52
- LEGN $32.42
- Resistance Level
- EHC $123.00
- LEGN $36.91
- Average True Range (ATR)
- EHC 2.05
- LEGN 1.42
- MACD
- EHC -0.40
- LEGN 0.02
- Stochastic Oscillator
- EHC 29.29
- LEGN 67.58
About EHC Encompass Health Corporation
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.